Anti-Cancer Potential of Rencofilstat Expanded with Results from Preclinical Multiple Myeloma Studies

January 18, 2023

https://www.globenewswire.com/news-release/2023/01/18/2591025/0/en/Anti-Cancer-Potential-of-Rencofilstat-Expanded-with-Results-from-Preclinical-Multiple-Myeloma-Studies.html

– Synergistic activity demonstrated with rencofilstat in combination with first line multiple myeloma drug, bortezomib –

EDISON, N.J., Jan. 18, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), fibrotic diseases, hepatocellular carcinoma (“HCC”), and other chronic diseases, today announced positive results of preclinical studies examining rencofilstat as a potential therapeutic for multiple myeloma (“MM”).

Read more at globenewswire.com

Related news for (HEPA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.